THE INDIAN PHARMACIST Official Circular Pharmacy LogoTHE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
CANONICAL MONOGRAPH [8.2] • ID: TIP-MED-000130

1. Amoxicillin + Clavulanic Acid (Co-amoxiclav)

2. Pharmacological Class: Aminopenicillin + Irreversible Beta-Lactamase Inhibitor Combination (Bactericidal Broad-Spectrum Beta-Lactam; WHO 'Access' Group) • 3. Therapeutic Category: Antimicrobials — Antibacterial & Antibiotic Agents (Ch 08)

⚖️ Compare Medicine

4. Clinical Overview & Verified Formulation Identity

Generic Name & Identifier:
Amoxicillin + Clavulanic Acid (Co-amoxiclav)
Code: [8.2] | Stable ID: TIP-MED-000130
Verified Indian Market Brands / Status:
Augmentin (GSK), Clavam (Alkem), Moxikind-CV (Mankind)
9. Dosage Forms & Strengths:
Oral Film-Coated Tablets: 625 mg (Amoxicillin 500 mg + Clavulanic Acid 125 mg), 375 mg (250/125 mg), 1000 mg Duo (875/125 mg); Paediatric Oral Suspension: 228.5 mg/5 mL, 457 mg/5 mL (Duo); IV Injection: 1.2 g (1000/200 mg), 600 mg; Oral Film-Coated Tablets: 625 mg (Amoxicillin 500 mg + Clavulanic Acid 125 mg), 375 mg (250/125 mg), 1000 mg Duo (875/125 mg); Paediatric Oral Suspension: 228.5 mg/5 mL, 457 mg/5 mL (Duo); IV Injection: 1.2 g (1000/200 mg), 600 mg
Route: Oral / Parenteral / Topical as specified by formulation
Indian Regulatory Schedule & NLEM Status:
Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945)
True

5 & 6. Mechanism of Action & Pharmacodynamics

Aminopenicillin + Irreversible Beta-Lactamase Inhibitor Combination (Bactericidal Broad-Spectrum Beta-Lactam; WHO 'Access' Group) acting on target receptor/enzyme pathways in Antimicrobials — Antibacterial & Antibiotic Agents (Ch 08): clinical efficacy is mediated via Aminopenicillin + Irreversible Beta-Lactamase Inhibitor Combination (Bactericidal Broad-Spectrum Beta-Lactam; WHO 'Access' Group) for Beta-lactamase-producing infections: Acute bacterial rhinosinusitis, acute exacerbation of COPD, community-acquired pneumonia, complicated urinary tract infections, diabetic foot infections, skin and soft-tissue infections, animal/human bites, and severe dental abscesses..

8. Therapeutic Indications

10. Dosage and Administration (Educational Reference Summary)

Dosing & Clinical Context: General Adult Reference: 625 mg (500/125 mg) three times daily (every 8 hours) or twice daily (for mild-to-moderate infections), OR 1000 mg (875/125 mg) twice daily (every 12 hours) for 5 to 7 days. Never substitute two 375 mg tablets for one 625 mg tablet (doing so doubles the clavulanic acid to 250 mg and causes severe diarrhoea!). Follow physician prescription.
Administration & Timing: MUST be taken AT THE START OF A MEAL! (Taking at the very beginning of breakfast, lunch, and dinner optimises clavulanate absorption and markedly reduces clavulanic-acid-induced gastrointestinal cramping and diarrhoea). | Every 8 hours (with breakfast, lunch, dinner for 625 mg TDS) or every 12 hours (with breakfast and dinner for 625 mg BD / 1000 mg BD).

11 & 13. Contraindications, Precautions and Warnings

🚫 11. Contraindications:
  • Strictly contraindicated in penicillin/beta-lactam allergy AND in patients with a history of Co-amoxiclav-associated cholestatic jaundice or hepatic dysfunction! Avoid in infectious mononucleosis.
⚠️ 13. Precautions and Warnings:

Renal: Strictly renal-function dependent! • Do NOT use the 1000 mg (875/125 mg) tablet if CrCl <30 mL/min! • CrCl 10–30 mL/min: 625 mg (500/125 mg) twice daily. • CrCl <10 mL/min: 625 mg once every 24 hours. Hepatic: Contraindicated in prior co-amoxiclav jaundice; monitor LFTs if used >10–14 days in liver disease.

7, 12, 14–18. Detailed Pharmacokinetics, Interactions, Special Populations & Counselling

7 & 16. Pharmacokinetics (ADME) & Renal / Hepatic Considerations

7. Pharmacokinetics (Absorption, Distribution, Metabolism, Excretion): Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.

16a. Renal Considerations: Renal: Strictly renal-function dependent! • Do NOT use the 1000 mg (875/125 mg) tablet if CrCl <30 mL/min! • CrCl 10–30 mL/min: 625 mg (500/125 mg) twice daily. • CrCl <10 mL/min: 625 mg once every 24 hours. Hepatic: Contraindicated in prior co-amoxiclav jaundice; monitor LFTs if used >10–14 days in liver disease.

16b. Hepatic Considerations: Renal: Strictly renal-function dependent! • Do NOT use the 1000 mg (875/125 mg) tablet if CrCl <30 mL/min! • CrCl 10–30 mL/min: 625 mg (500/125 mg) twice daily. • CrCl <10 mL/min: 625 mg once every 24 hours. Hepatic: Contraindicated in prior co-amoxiclav jaundice; monitor LFTs if used >10–14 days in liver disease.

12 & 14. Adverse Effects & Drug Interactions
12. Adverse Effects:
  • Antibiotic-associated diarrhoea (10–25%, driven by clavulanic acid stimulating small-bowel motility and altering flora), nausea, abdominal cramping, mucocutaneous candidiasis (thrush/vaginitis), skin rash.
  • Drug-Induced Cholestatic Jaundice / Hepatitis (clavulanic acid idiosyncratic reaction—more common in men and elderly patients >65 years, and can appear during therapy or up to 2 to 6 weeks AFTER completing the course!), anaphylaxis, C. difficile colitis, SJS/TEN.
14. Drug Interactions:
  • Warfarin / Acitrom: Potentiates anticoagulation and causes major INR spikes—check INR within 3–5 days of starting Augmentin! Allopurinol (increased rash)
  • Methotrexate (reduced renal clearance)
  • Mycophenolate mofetil levels reduced
15, 17 & 18. Special Populations, Clinical Monitoring & Patient Counselling

15. Use in Special Populations (Pregnancy, Lactation, Paediatrics, Geriatrics): Evaluate maternal-foetal benefit-risk ratio, paediatric mg/kg ceiling, and geriatric renal function prior to prescribing.

17. Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

18. Patient Counselling & Storage:
  • Patient Counselling Checklist: 1. Take right at the start of your meal to prevent loose motions. 2. Blister Moisture Alert: Clavulanic acid is extremely hygroscopic (absorbs humidity from Indian monsoon/summer air and turns soft, sticky, and dark brown, losing all potency)—keep strips sealed inside their outer aluminium desiccant pouch and never pop tablets out into weekly pill boxes in advance! 3. Reconstituted paediatric Augmentin Duo syrups MUST be stored in the refrigerator (2°C–8°C) and discarded after 7 days!
  • Meal & Clock Timing Instruction: MUST be taken AT THE START OF A MEAL! (Taking at the very beginning of breakfast, lunch, and dinner optimises clavulanate absorption and markedly reduces clavulanic-acid-induced gastrointestinal cramping and diarrhoea). (Every 8 hours (with breakfast, lunch, dinner for 625 mg TDS) or every 12 hours (with breakfast and dinner for 625 mg BD / 1000 mg BD).)
  • Missed Dose Protocol: Take with food as soon as remembered; maintain regular spacing for remaining tablets.
  • Geriatric Dispensing Pearl: Elderly men (>65 years) have the highest risk of clavulanate-induced cholestatic jaundice (which may present weeks after finishing the strip) and C. difficile diarrhoea. Avoid the 1000 mg strength if CrCl <30 mL/min.

Storage & Dispensing Notes: COLD CHAIN MANDATORY (2°C–8°C): Store in a pharmaceutical refrigerator between 2°C and 8°C; DO NOT FREEZE. Protect from light and heat during dispensing.

Visual Pharmacology Illustration (PLATE-8.9)

ANTIBACTERIAL MECHANISMS OF ACTION: CELL WALL, 30S/50S RIBOSOME, DNA & FOLATE 1. Cell-Wall Synthesis (Bactericidal) • Beta-Lactams (Penicillins, Cephalosporins, Meropenem): Inhibit PBPs (Transpeptidase) • Vancomycin: Binds D-Ala-D-Ala peptide • Fosfomycin: Inhibits MurA enolpyruvyl PK/PD: Time-dependent (fT > MIC) 2. 30S Ribosomal Subunit • Aminoglycosides (Gentamicin, Amikacin): Irreversible 30S binding & mRNA misreading (Bactericidal; Cmax/MIC; Ototoxic/Nephrotoxic) • Tetracyclines (Doxycycline) & Tigecycline: Block aminoacyl-tRNA binding at 30S A-site 3. 50S Ribosomal Subunit • Macrolides (Azithromycin, Clarithromycin) & Clindamycin: Block 23S rRNA translocation • Linezolid: Blocks 70S initiation complex (MRSA/VRE) • Chloramphenicol: Inhibits peptidyl transferase Mostly bacteriostatic (Linezolid vs Staph/Strep) 4. Nucleic Acid Synthesis (DNA Gyrase & RNA Pol) • Fluoroquinolones (Ciprofloxacin, Levofloxacin, Moxifloxacin): Inhibit DNA Gyrase (Topoisomerase II) & Topoisomerase IV (Bactericidal) • Rifampicin: Inhibits bacterial DNA-dependent RNA polymerase (β-subunit) • Metronidazole: Reduced nitro group forms free radicals that strand-break DNA 5. Folate Pathway & Cell Membrane Disruptors • PABA → [Sulfamethoxazole blocks Dihydropteroate Synthase] → Dihydrofolate • Dihydrofolate → [Trimethoprim blocks DHFR] → Tetrahydrofolate (Co-trimoxazole) • Polymyxins (Colistin): Bind LPS outer membrane of MDR Gram-negative bacilli • Daptomycin: Ca2+-dependent membrane depolarisation of Gram-positive cocci (MRSA)
Figure 8.9: Mechanisms of action of major antibacterial classes across bacterial cell-wall synthesis, 30S/50S ribosomal protein translation, nucleic acid replication, and folic acid biosynthesis.

19. Authoritative References & Source Traceability

Primary Reference Record: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 08 [8.2] (p. 93)

Verification Portals: Indian Pharmacopoeia Commission (IPC) • CDSCO (India Jurisdiction) • NCBI Bookshelf • DailyMed (US FDA Label Reference)

Last Reviewed Date: 2026-11-08 • Related Study Guide: Antimicrobial Stewardship & PK/PD Optimization →